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Abstract
During the 1990s, most diabetic ulcers were considered neuropathic, but the
Eurodiale study showed that more than 50% of these were non-plantar (neuro-
ischaemic and ischaemic). According to the International Guidelines, the neuro-
ischaemic and ischaemic diabetic foot ulcer (DFU) outcomes are connected to
factors related to the wound, leg-associated factors and patients’ comorbidities.
We used wound, ischaemia and foot infection (WIfI) classification system; Trans-
Atlantic Inter-Society Consensus-II (TASC-II) arterial lesion score; and Kaiser
Permanente pyramid (stratification of patients according to their complexity) for
assessing these parameters. From February 2011 to June 2012, we collected 124
episodes of neuro-ischaemic and ischaemic active ulcer in 100 patients: 18 required
major amputation, 14 of them were in WIfI stage 4 and 4 in WIfI stage 3. Ten
patients (over 14 in WIfI stage 4) were classified as TASC-II D. Eight patients (over
the same 14) were classified as the higher risk of Kaiser Permanente pyramid. In
line with other studies, our data support that the WIfI classification correlates well
regarding risk of amputation at 1 year. However, when adding TASC-II and Kaiser
Permanente pyramid assessment, the outcome is even more accurate not only for
limb salvage but also for patients’ survival.
Keywords: critical limb ischaemia, chronic limb-threatening ischaemia, diabetic
foot ulcers, diabetic foot ulcer classification systems, outcome predictors
1. Introduction
Nowadays, diabetes is considered as a leading cause of non-traumatic amputa-
tion all around the world. Despite the high morbidity and mortality associated with
diseases of the foot in diabetes and although it is costly to both healthcare providers
and the patient and their families [1], it is a topic that has generally failed to attract
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the same level of interest by healthcare professionals as other diabetes
complications.
The concept of critical limb ischaemia (CLI) implies that there are objective
values that inform about the perfusion below which, if we do not increase the blood
supply, the limb will be lost. CLI was defined for the first time in 1982 as rest pain
with ankle pressure < 40 mmHg or necrosis and ankle pressure < 60 mmHg [2]. In
2017 the European Society of Cardiology and the European Society for Vascular
Surgery (ESC/ESVS) guidelines on the diagnosis and treatment of peripheral arte-
rial disease (PAD) have replaced the term critical limb ischaemia with chronic limb-
threatening ischaemia (CLTI). The authors gave three arguments for this change:
first, not all patients are in a “critical” situation even if they are not revascularized.
Second, due to change in the population affected, mostly diabetics with neuro-
ischaemic ulcers, it was recognized that severe ischaemia was not the only underly-
ing cause. And finally, the risk of amputation does not only depend on the extent of
ischaemia but also on the presence of wound and infection [3].
According to the World Health Organization (WHO), the diabetic foot may be
defined as a group of syndromes in which neuropathy, ischaemia and infection lead
to tissue breakdown, resulting in morbidity, possible amputation and mortality [4].
It is admitted that ischaemic and neuro-ischaemic ulcers have similar behaviour
to each other compared to the neuropathic ones referred to major amputation and
survival [5].
Before the Eurodiale study, published in 2007 [6], it was widely believed that
most diabetic ulcers were neuropathic, but this study found that:
• More than 50% (52%) of the foot ulcers were non-plantar (ischaemic and
neuro-ischaemic).
• More than 50% (58%) of patients with an ulcer had signs of infection.
• One third of the patients (31%) had signs of both peripheral arterial disease
and infection. These patients have a worse prognosis; they take longer to heal
and have more amputations and more risk of dying. They have a distinct
profile: they are older and have more non-plantar ulcers, greater tissue loss and
more serious comorbidities.
The results from the Eurodiale study underlined that not only ulcer healing
depends on the wound, the limb and the patient, but also the future of the extremity
and patient survival too.
The International Guidelines [7] have published similar results: the
neuro-ischaemic and ischaemic diabetic ulcer outcome is connected to:
• Factors related to the wound (the most important is the extent of tissue
involvement).
• Limb-related factors (in these cases severity of PAD).
• Patients’ comorbidities (see Figure 1).
Apelqvist in 1151 patients with diabetes and CLTI confirmed the three above-
mentioned factors. Moreover, revascularization is the major driver for ulcer healing.
In fact, both percutaneous transluminal angioplasty (PTA) and open vascular sur-
gery increased the probability for primary healing with an odds ratio (OR) of 1.77
and 2.05, respectively [8].
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However, data about natural history of the disease are scarce. Elgzyri in 602
patients with diabetic foot ulcer (DFU) who had been considered as CLTI and were
not revascularized reported that [9]:
• 50% healed primarily with wound care or with minor amputation
• 17% healed, but after a major amputation
• 33% died with limbs intact but with unhealed wounds
1.1 Multidisciplinary team approach
Dr. Joslin, the famous American diabetologist, observed that after the introduc-
tion of insulin, “the mortality from diabetic coma had fallen dramatically (from 60
to 5%) yet deaths from diabetic gangrene of the foot and leg had risen significantly”.
He believed that diabetic gangrene was preventable and his remedy was a team
approach involving nurses, surgeons and podiatrists for limb salvage and foot care.
He was also the first to advocate for teaching patients to care for their own diabetes
and the first who named diabetes as a serious public health issue that was becoming
a pandemic [10].
Dr. Edmonds in 1979 in UK recognized the need for coordinated intensive care
of patients with diabetic foot with input from several disciplines, including
diabetology, medicine, orthopedics and vascular surgery as well as podiatrists,
orthotists and nurses. This initiative resulted in an immediate 50% reduction in
major amputations (1984). Specific emphasis was placed on podiatric debridement,
off-loading, infection control and diabetes care [11].
The diabetic rapid response acute foot team (DRRAFT) guidelines [12],
published in 2009, suggest that the vascular surgeon and diabetic podiatrist consti-
tute the minimum in the formation of a diabetic foot team.
The authors defined seven vital skills for such a team to be able to effectively
manage the lower-extremity complications of diabetes (see Table 1).
The Multidisciplinary Diabetic Foot Unit (MDFU) was introduced at our insti-
tution in February 2011. The team was working in three levels of care: primary
prevention, acute patients’ treatment and outpatient postoperative management.
Day-to-day care was carried out by a podiatrist and a vascular surgeon, the basic
American “toe and flow” approach [13]. An algorithm for urgent referral was
introduced in our Unit regarding the ulcer, the leg and the patient (see Figure 2).
Figure 1.
Contributors to the neuro-ischaemic and ischaemic diabetic foot ulcers (DFUs) outcomes. *PAD, peripheral
arterial disease; **CO-MORB, comorbidities.
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1.2 Understanding diabetic foot ulcer classifications
Classifications that we use in daily clinical practice are compartmentalized: some
refer only to infection, and others only to ischaemia or only treat descriptive aspect
of ulcers [14] (see Table 2).
Monteiro-Soares in a meta-analysis published in 2014 identified 25 different
classification systems for diabetic foot ulcers. Of those, eight used a descriptive
basis, and seven utilized prognostic stratification classification systems, but few
studies evaluated their reliability or external validity [15].
The International Working Group on Diabetic Foot (IWGDF) has published
in 2019 his updated guidelines on the prevention and management of diabetic foot
disease with a new and special chapter focus on the classification of active diabetic
foot ulcers. The authors identified eight key factors judged to contribute to the
scoring of classifications: some are patient-related (e.g., end-stage renal failure
Haemodynamic and anatomic vascular assessment with revascularization, as necessary
Biomechanical and podiatric assessment with surgical and non-surgical intervention as necessary
Peripheral neurological examinations
Wound assessment and staging/grading of infection and ischaemia
Site-specific bedside and intraoperative incisions and debridement, taking samples for culture using an
appropriate technique
Initiate and modify culture-specific and patient-appropriate antibiotic therapy
Conduct appropriate postoperative monitoring to reduce risks of re-ulceration
Table 1.
Minimum skills for constituting a diabetic foot team from DRRAFT [12].
Figure 2.
Multidisciplinary diabetic foot unit organization (toe and flow inspired). GP, general practitioner; ER,
emergency room; N&E, nurses and endocrinologist; CV, cardio vascular; iv AB, intravenous antibiotics.
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(ESRF)); others, limb-related (e.g., PAD and loss of protective sensation) and lastly
ulcer-related (area, depth, site, single or multiple and infection). They identified
five clinical key situations too and recommended one specific classification for each
one: communication among health professionals; predicting the outcome of an
individual ulcer; aid to clinical decision-making for an individual case; assessment
of a wound, with or without infection, and peripheral artery disease; and audit of
outcome in local, regional or national populations [16–18] (see Tables 3–5).
In order for a stratification system of a disease to be relevant, it is expected that
it will give us a risk scale with respect to natural history and that the classification is
detailed enough to compare different treatments. Thus, the scale could be descrip-
tive and predictive at the same time. In January 2014 the Society for Vascular
Surgery (SVS) published the new classification system for CLTI based on wound
extent, degree of ischaemia and foot infection (WIfI), with scales from 0 to 3, for
each one of these parameters [19].
Classification
system
Main points Pros/cons
Meggitt-Wagner Assesses ulcer depth plus the
presence of gangrene and loss of
perfusion using six grades (0–5)
Well established
Conversely, infection and ischaemia
are not fully addressed
Texas University Assesses ulcer depth, infection and
ischaemia using a matrix of four
grades combined with four stages
Well established
Describes infection and ischaemia
better than Meggitt-Wagner but
informs only about yes or no (is not
categorized). May help in predicting
the outcome of DFUs
PEDIS
Perfusion, extent (size),
depth (tissue loss),
infection and sensation
(neuropathy)
Developed by IWGDF
Uses four grades (1–4)
User-friendly (clear definitions, few
categories) for practitioners with a
lower level of experience with
diabetic foot management
SINBAD
Site, ischaemia,
neuropathy, bacterial
infection, area and depth
It grades area, depth, infection
arteriopathy and neuropathy and
site. Uses a scoring system to help
predict outcomes and enable
comparisons between different
settings and countries
Simplified version of the S (AD)
SAD classification system.
Includes ulcer site as data suggests
this might be an important
determinant of outcome
Table 2.
Pros and cons of some common wound classification systems for DFUs [14].
Clinical scenario Classification recommended
Communication among health professionals *SINBAD
Predicting the outcome of an individual ulcer None
Assessment of infection **IDSA/IWGDF#
Assessment of perfusion and the likely benefit of revascularization WIfI##
Audit of outcome in local, regional or national populations SINBAD
*SINBAD, site, ischaemia, neuropathy, bacterial infection, area and depth.
**IDSA, Infectious Diseases Society of America.
#IWGDF, International Working Group on Diabetic Foot.
##WIfI, Wound, Ischaemia and foot Infection.
Table 3.
IWGDF classification system recommendations [16].
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WIfI classification represents a summary of multiple previously published clas-
sifications focused on diabetic foot ulcers and pure ischaemia or infection models
and is the first one which reports on the risk of amputation and benefit of revascu-
larization at 1 year.
With respect to the wound, WIfI integrates the Texas University classification
that is validated and adds the gangrene component. The authors include pain at rest
and gangrene of ischaemic cause. Depth takes preference over extension, and there
is a measure of what is going to lose (see Table 6).
WIfI ischaemia is stratified not only according to ankle-brachial index (ABI)
figures but also ankle pressure and digital pressure. They are categorized up to
moderate degrees of ischaemia. Alternatives to the ABI are included, and digital
pressure is considered mandatory in diabetic patients (see Table 7).
WIfI collects the characteristics of the Infectious Diseases Society of America
(IDSA) (validated) and the IWGDF (see Table 8).
Based on the results obtained in each parameter, a Delphi survey among 12
experts was conducted. A table for estimating the risk of major amputation over the
first year and the theoretical benefit of revascularization was elaborated.
Category Definition Score
Site Forefoot
Midfoot and hindfoot
0
1
Ischemia Pedal blood flow intact (at least one palpable pulse)
Clinical evidence of reduced pedal flow
0
1
Neuropathy Protective sensation intact
Protective sensation lost
0
1
Bacterial infection None
Present
0
1
Area Ulcer <1 cm2
Ulcer >1 cm2
0
1
Depth Ulcer confined to the skin and subcutaneous tissue
Ulcer reaching the muscle, tendon or deeper
0
1
Total possible score 6
Table 4.
SINBAD classification system [17].
Clinical manifestations Infection
severity
PEDIS
grade
Wound lacking purulence or any manifestations of inflammation Uninfected 1
Presence of >2 manifestations of inflammation (purulence, erythema,
tenderness, warmth or induration), but any cellulitis/erythema extends
<2 cm around the ulcer, and the infection is limited to the skin or superficial
subcutaneous tissues; no other local complications or systemic illness
Mild 2
Infection (as above) in a patient who is systemically well and metabolically
stable but which has >1 of the following characteristics: cellulitis extending
>2 cm, lymphangitic streaking, spread beneath the superficial fascia, deep
tissue abscess, gangrene and involvement of muscle, tendon, joint or bone
Moderate 3
Infection in a patient with systemic toxicity or metabolic instability (e.g.
fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis,
acidosis, severe hyperglycemia or azotemia)
Severe 4
Table 5.
IDSA/IWGDF system [18].
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Wound grade Diabetic foot ulcer (DFU) Gangrene
0 No ulcer
Clinical description: minor tissue loss
(1 or 2 digits)
No gangrene
Salvageable with simple digital amputation or
skin coverage
1 Small, shallow ulcer(s) on distal leg or
foot; no exposed bone, unless limited to
the distal phalanx
Clinical description: minor tissue loss
(1 or 2 digits)
No gangrene
Salvageable with simple digital amputation or
skin coverage
2 Deeper ulcer with exposed bone, joint
or tendon; generally, not involving the
heel; shallow heel ulcer, without
calcaneal involvement
Clinical description: major tissue loss
Gangrenous changes limited to digits
Salvageable with multiple (>3) digital
amputation or standard trans-metatarsal
amputation (TMA)  skin coverage
3 Extensive, deep ulcer involving the
forefoot and/or midfoot; deep full-
thickness heel ulcer  calcaneal
involvement
Clinical description: extensive tissue
loss
Extensive gangrene involving the forefoot and/
or midfoot; full-thickness heel necrosis and
calcaneal involvement
Salvageable only with a complex foot
reconstruction or non-traditional TMA
(Chopart or Lisfranc) flap coverage or
complex wound management needed for large
soft tissue defect
Table 6.
Wound from WIfI system [19].
Ischemia
grade
Ankle-brachial
index
Ankle systolic pressure
(mmHg)
Toe pressure, trans-cutaneous oxygen
pressure (mmHg)
0 >0.80 >100 >60
1 0.6–0.79 70–100 40–59
2 0.4–0.59 50–70 30–39
3 <0.39 <50 <30
Table 7.
Ischemia from WIfI system [19].
Foot infection grade Clinical manifestations
0 No symptoms or signs of infection
Infection present, as defined by the presence of at least 2 of the following items: local
swelling or induration; erythema >0.5 to <2 cm around the ulcer; local tenderness or
pain; local warmth; purulent discharge: thick, opaque to white or sanguineous secretion
1 Local infection involving only the skin and the subcutaneous tissue (without
involvement of deeper tissues and without systemic signs as described below). Exclude
other causes of an inflammatory response of the skin (e.g. trauma, gout, acute Charcot,
neuro-osteoarthropathy, fracture, thrombosis, venous stasis)
2 Local infection (as described above) with erythema >2 cm, or involving structures
deeper than the skin and subcutaneous tissues (e.g. abscess, osteomyelitis, septic
arthritis, fasciitis), and no systemic inflammatory response signs (as described below)
3 Local infection (as described above) with the signs of SIRS, as manifested by two or more
of the following: temperature > 38°C or < 36°C; heart rate > 90 beats/min; respiratory
rate > 20 breaths/min or PaCO2 < 32 mmHg; white blood cell count >12,000 or < 4000
cu/mm or 10% immature (band) forms
Table 8.
Foot infection from WIfI system [19].
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When calculating the benefit of revascularization, they assume that the infection
is controlled. Intraclass correlation coefficient for the amputation in the first year
was 0.81/0.98 and for the benefit of revascularization 0.76/0.97 (see Table 9).
2. Looking at the big picture
In a recent meta-analysis published in 2019 regarding the prognostic value of the
WIfI classification in patients with CLTI and where 12 studies comprising 2669
patients were evaluated, the authors conclude that “the likelihood of an amputation
after 1 year in patients with CLTI increases with higher WIfI stages”. But, “the
current evidence is not sufficient for the instrument to be helpful in clinical decision
making for patients with CLTI and prospective studies are needed to determine its
role in clinical practice” [20]. We are aware that the risk of amputation increases as
the WIfI clinical stage progresses from stage 1 to stage 4. However, data regarding
those with PAD and their anatomical conditions and patients’ comorbidities are
lacking in WIfI classification system. By better defining and understanding CLTI
spectrum, we need to include arterial lesion classification and patients’
comorbidities.
Table 9.
WIfI prediction tables. Adapted from the original [19].
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Existing systems of classification of critical ischaemia (e.g., classical Fontaine
and Rutherford) do not adequately explain the extent of tissue loss or the presence
and severity of infection. In recent years, most classifications have focused on
anatomical details extracted from arteriography without paying attention to the
physiological state of the limb, for example, the Bollinger, Graziani and Trans-
Atlantic Inter-Society Consensus (TASC-I and TASC-II) classifications. Although
there are criticisms, the TASC-I and TASC-II classifications are the only ones that
carry recommendations for treatment [21] (see Figure 3). And we should also use a
classification that describes the state of the arteries in the foot [22].
If we assume that in ulcer healing, factors are related not only to the wound itself
but also to the limb and the patients are involved, we need an objective scale that
indicates the type of patient we are treating. For this purpose, among other scales
(e.g. Prevent III and Finnvasc), we have included the categorization of the chronic
pluripathological patient adopted by Osakidetza-Servicio Vasco de Salud
(Osakidetza-SVS, Basque Country National Health Service) in 2011 based on the
good practice model of Kaiser Permanente. Chronic patients are stratified into three
levels of intervention depending on the complexity of the case. At the baseline of
the Kaiser Permanente pyramid, the healthy members of the population are located
for whom prevention, health promotion and risk factor control interventions are a
priority. In the first level, where the majority of chronic patients we find concen-
trated, the interest is focused on promoting self-care. In the second level are chronic
patients with the prominence of a particular disease or organ and who can benefit
from the “disease management”, and, finally, in the highest level of the pyramid are
those patients with very complex cases that need integral management. Although
they are not the most numerous, these are the ones that consume the most resources
[23] (see Figure 4).
Other scales used in vascular surgery units are Prevent III and Finnvasc. Prevent
III was designed to calculate the amputation-free time after revascularization sur-
gery and consists of a scoring system on various pathologies: dialysis 4 points, tissue
loss 3 points, age ≥ 75 years 2 points, hematocrit ≤30% 2 points and coronary
disease 1 point. A low risk ≤3, medium risk 4–7 or severe risk ≥8 points is attributed
according to the score obtained [24]. Finnvasc score seems to behave better also
when predicting the immediate postoperative outcome [25]. The accuracy of these
scales is acceptable. They are easy to use and very valuable in clinical practice,
especially to help us decide when not to revascularize.
2.1 Population in our study
Based on this background, as part of a doctoral thesis [26], we collected retro-
spectively our data. The aim of the study was to evaluate the implementation of the
WIfI classification mainly on the risk of major amputation and benefit of revascu-
larization at 1 year in a population diagnosed with CLTI and neuro-ischaemic or
pure ischaemic wounds and diabetes. Adding up the TASC-II classification to have
more information on the arterial status of the limb and the result of applying the
Kaiser Permanente pyramid to better profile the type of patient affected.
It is a retrospective and observational study based on episodes of active ulcer in
patients with diabetes collected in a prospective database open from the beginning
of the care activity related to the creation of the Multidisciplinary Diabetic Foot
Unit at Cruces University Hospital.
From February 2011 to June 2012, we treated 122 consecutive patients (151 epi-
sodes) with diabetic foot ulcer. The median age was 70 years (SD 11.35). Men are
73.8%. The median HbA1c was 62.8 mmol/mol (7.9%). Hypertension was present in
82% of our population, coronary artery disease in 53%, chronic kidney disease in 38%
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and 6.0% on dialysis. We retrospectively collected data on 124 (82.11%) ischaemic
and neuro-ischaemic ulcers; 27 pure neuropathic (17.89%) were excluded from the
study. Therefore 115 ulcers in 93 patients were the final population (see Figure 5).
To verify the influence of the different factors on the time to amputation, the
survival of the patients or until healing, wemake use of Kaplan–Meier tables. A univar-
iate andmultivariate Cox regression has also been carried out using a non-automatic
steppingmethod. A level of statistical significance p < 0.05 has been considered for all
tests. The statistical analysis was carried outwith the SPSS program vs. 22.0.
2.2 Our results
In our study 72.6% of patients were revascularized. We follow the
“endovascular-first” policy, but whether the intervention was endovascular or open
is not specified. We had 18 (14.5%) major amputations at one year. Fourteen of
them (78%) were in WIfI stage 4 and 4 (22%) in WIfI stage 3 (see Table 10). The
positive likelihood ratio (LR) was 1.40 (95% CI = 1.04–1.89); and the negative LR
Figure 3.
Modified from TASC-II classification system including below the knee (BTK) lesions [21].
Figure 4.
Adapted from the Kaiser Permanente pyramid model [23].
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was 0.5 (95% CI = 0.20–1.23). In the negative LR, if a patient was in stage 1, 2 or 3,
he/she had double probability for limb salvage than in stage 4.
Regarding the benefit of revascularization, we compared patients classified as
high benefit versus those of moderate and low benefit. Those of very low benefit
were excluded because the intervention would not really be indicated. The positive
LR was 2.08 (95% CI = 1.39–3.13) and negative LR 0.00. Thus, the probability that a
patient with a high benefit of being revascularized according to the WIfI scale, if
this intervention is performed, saves the limb is 73.1%.
In our study the analysis of the area under the receiver operating characteristic
(ROC) curve (AUC) regarding the predictive ability related to amputation risk at
1 year was 0.61 (95% CI = 0.47–0.74) (see Figure 6).
2.2.1 Survival function for major amputation
In our population the median time for suffering a major amputation was
4.01 years (95% CI = 3.69–4.31). Patients who had not undergone prior amputation
Figure 5.
Population under study [26].
WIfI amputation risk at 1 year No Yes Total
Very low, Number
%
5
100.0
0
0.0
5
100.0
Low, Number
%
12
100.0
0
0.0
12
100.0
Moderate, Number
%
30
88.2
4
11.8
34
100.0
High, Number
%
59
80.8
14
19.2
73
100.0
Total Number
%
106
85.5
18
14.5
124
100.0
Table 10.
Number of major amputations at 1 year according to WIfI [26].
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and those who had only a minor one take a median of 4.08 years (95% CI = 3.77–
4.40) and (95% CI = 3.47–4.69), respectively. Patients who had suffered a previous
major amputation were amputated in a median of 1.76 years (95% CI = 0.76–2.77);
the difference was statistically significant p < 0.001 (see Figure 7).
Patients in TASC A, B and C take a median of 4.14 years (95% CI = 3.921–4.367)
to suffer a major amputation, whereas patients classified as TASC D took a median
of 3.75 years (95% CI = 3.306–4.200). The difference was statistically significant
p = 0.009 (see Figure 8).
We found statistical differences regarding the amputation rate only when WIfI
stages 1, 2 and 3 were compared with stage 4. Patients classified according to the
WIfI scale as very low, low and moderate risk of being amputated during the first
year underwent such amputation in a median of 3.92 years (95% CI = 3.60–4.23).
And those classified as high risk presented it in a median of 3.73 years (95%
CI = 3.27–4.18), p = 0.044 (see Figure 9).
Patients with small lesions take a median of 3.90 years to be amputated (95%
CI = 3.58–4.23); those with a major lesion took 4.01 years (95% CI = 3.58–4.43)
compared to those who had extensive wound that took 1.35 years (95% CI = 0.21–
2.48); the difference was statistically significant p < 0.001 (see Figure 10).
Cox regression multivariate analysis identified previous major amputation,
TASC D arterial lesions and extensive ulcer from WIfI (but no global WIfI) as
independent risk factors for major amputation (see Table 11).
2.2.2 Survival function for survival
We must not forget that we are facing elderly and pluripathological patients.
The median survival was 3.42 years (95% CI = 3.08–3.76). Patient’s survival was
84% at 1 year, 66% at 3 years and 50% at 5 years. Five years after the diagnosis of
CLTI, only half of the population survived regardless of whether the limb was saved
or amputated (see Figure 11).
Figure 6.
Area under the ROC curve [26].
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Figure 7.
Survival function for major amputation according to previous one [26].
Figure 8.
Survival function for TASC-II major amputation risk at 1 year comparing a, B and C versus D.
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Figure 9.
Survival function for WIfI major amputation risk at 1 year stages 1, 2 and 3 compared with stage 4 [26].
Figure 10.
Survival function for major amputation according to wound from WIfI.
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In our study, 51% of patients were in the Kaiser Permanente pyramid highest
risk zone. Patients who did not reach the top of the pyramid survive a median of
4.25 years (95% CI = 3.88–4.62), and those who accumulate more pathology survive
a median of 3.30 years (95% CI = 2.90–3.70), p < 0.001 (see Figure 12).
The Cox regression multivariate analysis has shown that only the stratification of
the pluripathological patient according to the Kaiser Permanente model is an inde-
pendent risk factor for death. The most pluripathological patients are classified at
the top of the pyramid (red color) and have a risk of dying 8.27 times higher (95%
CI = 2.48–27.59).
2.2.3 Survival function for wound healing time (WHT)
The median time for ulcer healing, in our study, was 7.65 months (95%
CI = 5.723–9.587) which is equal to 230 days.
Previous history of amputation influences wound healing time. Thus, in patients
with no past history of amputation, the medianWHTwas 13.4 months (95% CI = 9.65–
17.20); in those with a minor amputation, 15.7 months (95% CI = 10.34–21.20); and in
patients with a major one, 34.5 months (95% CI = 23.50–45.55), p = 0.006.
HR 95% CI
p-value HR Inferior Superior
No previous amputation (reference) <0.001
Yes, minor 0.987 0.987 0.197 4.934
Yes, major <0.001 20.720 6.013 71.406
TASC D (recoded) 0.003 27.952 3.000 260.452
WIfI extensive lesion (reference) 0.016
Small lesion 0.194 2.248 0.662 7.632
Major lesion 0.004 11.868 2.184 64.490
Table 11.
Cox regression multivariate analysis for major amputation.
Figure 11.
Patient’s survival function [26].
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As the arterial lesions become more complex according to TASC-II and more
extensive according to WIfI, wound healing time is longer, p = 0.005 and p
< 0.001, respectively. There is more information about WHT in a previous paper
published by our group in 2017 [27].
Patients who followed podiatric treatment take a median of 7.5 months in
healing (95% CI = 6.14–9.03) and those who did not take a median of 12 months
(95% CI = 2.18–22.00), p = 0.012. Unfortunately, this factor was only significative
at Cox regression univariate analysis.
Cox regression multivariate analysis identified previous amputation, TASC-II
classification and wound fromWIfI (but no global WIfI) as independent risk
factors for wound healing (see Table 12).
HR 95% CI
p-value HR Inferior Superior
TASC D (reference) <0.001
TASC A 0.001 6.672 2.206 20.181
TASC B <0.001 5.517 2.208 13.783
TASC C 0.028 1.828 1.068 3.126
Extensive lesion (reference) 0.040
Small 0.025 9.959 1.336 74.252
Major 0.057 6.985 0.946 51.580
Previous major amputation (reference) 0.008
No amputation 0.010 13.696 1.868 100.391
Minor amputation 0.044 8.099 1.060 61.874
Table 12.
Cox regression multivariate analysis for wound healing time [26].
Figure 12.
Survival function comparing low and median levels with high level at Kaiser Permanente pyramid [26].
16
Diabetic Retinopathy
2.3 Discussion
Reviewing the van Reijen meta-analysis which compares the best methodologi-
cal 12 scientific papers published until June 2018 focused on the prognostic value of
the WIfI classification in patients with CLTI, only one study included exclusively
patients with diabetes, whereas others excluded them.
Regarding treatment, six studies included revascularized patients in different
ways, and the other six also included patients with conservative treatment.
The prognostic value of the WIfI classification was studied retrospectively (as in
our study) in all but one which implies a certain risk of information bias. Five
studies performed a multivariate analysis for the WIfI classification on major
amputation, but in four of them, clinical stage or reference was not reported.
The authors recognize that the likelihood of a major amputation after 1 year in
patients with CLTI increases with higher clinical WIfI stages, especially in stage 4 in
spite of diverging range of patients included (hospitalized/outpatients; requiring
hemodialysis or not; invasively or conservative treatment; diabetics/non-diabetics;
etc.). This could, partly, explain the statistical heterogeneity that they found.
Although the concept of the WIfI classification is well designed, it only considers
the status of the affected limb with neither additional information related to vascu-
lar anatomy involved nor patients’ comorbidities [20] (see Tables 13 and 14).
2.4 Conclusions
In conclusion, in our study, we identified a previous amputation, TASC-II clas-
sification and wound fromWIfI (but no global WIfI) as independent risk factors for
major amputation and wound healing time. And, among other comorbidities, only
%Major amputation >1 year % AFS >1 year % Limb salvage >1 year
WIfI I 0 83 95
WIfI II 8 76 92
WIfI III 11 75 91
WIfI IV 38 55 61
Table 13.
Results of van Reijen meta-analysis [20].
Cull Zhan Causey Beropoulis Darling Ward Vela
Age (years) 70 +/ 11 58 +/ 16 66 77 +/ 15 71 +/ 12 62.8 70 +/ 11
Males % 62 79 62 61 53 — 74
HbA1c % — — — — — — 7.9
DM % 66 93 76 0 77 72 100
Prevent III at high risk — — 17% 5.2 +/ 2.4 — — —
Kaiser high risk level % — — — — — — 51
Hypertension % 93 86 85 — 84 84 82
CAD % 63 55 47 54 49 — 53
CKD % — 41 — 37.5 23 — 38
Dialysis % 14 20 23 15.5 18 — 6
Table 14.
Population comparison from some studies included on van Reijen meta-analysis and our study.
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the stratification of the pluripathological patient according to the Kaiser
Permanente model was recognized as an independent risk factor for death.
Of course, our study has certain limitations: it is retrospective but is based on
test and images included in our electronic database. The population is small, and we
need to recode some items in order to increase statistical significance. Moreover,
our patients are in-hospital, with CLTI and diabetes. But our goal was “the better
definition of the population, the better accuracy of the results”. Infection was no
significant because it was controlled on antibiotics.
In line with other publications, our data support that the WIfI classification
system correlates well with clinical outcomes regarding risk of amputation at one
year and WHT. However, when adding TASC-II and, in our case, Kaiser
Permanente pyramid assessment, the outcome is even more accurate not only for
limb salvage but also for patients’ survival.
Considering all this information, not onlymore prospective studies if not a new three-
dimensional score capable to predicting the outcome of an individual ulcer paying atten-
tion to the better characterization of the population involved should be implemented.
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